These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 19432987)

  • 1. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
    Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D
    BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
    Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
    Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
    Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
    Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
    Buck E; Eyzaguirre A; Brown E; Petti F; McCormack S; Haley JD; Iwata KK; Gibson NW; Griffin G
    Mol Cancer Ther; 2006 Nov; 5(11):2676-84. PubMed ID: 17121914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
    Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
    World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
    Tao JJ; Castel P; Radosevic-Robin N; Elkabets M; Auricchio N; Aceto N; Weitsman G; Barber P; Vojnovic B; Ellis H; Morse N; Viola-Villegas NT; Bosch A; Juric D; Hazra S; Singh S; Kim P; Bergamaschi A; Maheswaran S; Ng T; Penault-Llorca F; Lewis JS; Carey LA; Perou CM; Baselga J; Scaltriti M
    Sci Signal; 2014 Mar; 7(318):ra29. PubMed ID: 24667376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.